Get started

Undervalued

The bigger picture for weed This is a 1-month chart, which enables us to see the very long-term trend. Honestly nothing is really happening yet, we maintain a consolidation for almost a year, after a long-term heavy decline. Fundamentally, nothing has shifted yet, but it looks like there is some interest with Biden getting nominated. Stocks are undervalued; that doesn't mean they can become even more undervalued. I am watching them, but don't feel the time is right yet. If you don't want to miss out, buy a 25% of what you would normally. I am keeping them on a watchlist.
AMEX:MJ
by dorfmanmaster
Undervalued Steel BreakoutTechnical Analysis We have a breakout on strong intraday volume (200% above 10-day average). RSI @67 - still not overbought. OBV has been supportive. Because we are in a longer down-trend, we will see multiple resistance; which will very helpful to set your limits. Risk reward ratio is great, using $32.3 as stop-limit loss, and $39 as a sell-exit. Be careful of a fake break-out, as this is only the 1st day. Fundamental Analysis One of the infrastructure plays with expected fiscal stimulus, could be steel. As price is king, it tells a more accurate story of what market makers think of the upcoming events.
AMEX:SLX
by dorfmanmaster
MMED, The Second Psychedelic Stock That Will Reach NASDAQAs some of you have witnessed CMPS IPO climb from 17$ to 43$ in 3 days, most of investors wonder what is the next psychedelic stock that will perhaps result in the same behavior. Of course, a lot of stocks from the psychedelic sector are still penny stocks and mostly Canadian stocks. Penny Stocks are a scary investment to some of you and I completely can relate and understand this. However, remember that around 3-5% of Penny Stocks still can be valuable stocks. But in any case, I am not here to convince you to invest in Penny Stocks or not, I am here to predict which one will rise and will have a very promising returns. The stock that I predict a strong rise called MMED or Mind Medicine, A Canadian penny stock traded on NEO exchange. The stock is a small cap, around 325 Million Dollars. Which leaves us a lot of space for a good long term rise. The stock by the time I write is around a 1.09$ and I am riding this stock from July, where it was around 0.45$. Around 6 weeks ago, MMED announced a NASDAQ up-listing, and rumors speculate that MMED will do a reverse split 4:1 in order to get the minimum price 4$ to be able to up-list on NASDAQ. In my experience, the stock is very reactive to news and rumors, and any announce of good news, will drive the stock 10% up minimum easily. Most of USA investors are not allowed to invest in Penny Stocks from any other exchange than NASDAQ, this is a good opportunity to buy this stock now and retail it on the NASDAQ up-listing to other investors. Of course, everything has a risk, and as MMED says, they do not guarantee to be accepted by NASDAQ, but once there is a confirmation, this stock will very bullish until the date to up-listing. I predict the price will hit minimum 2$ a share before NASDAQ, and once we up-list on NASDAQ, whether there was a reverse split or not, the day of up-listing will drive the stock minimum from 150% to 300% or more. Edit: I do not take responsibility for any of your investment, strong return always represents a strong risk.
MLong
by DumpItAgain
5
GSK - Price Target: 38.00 By November 20th~GSK Stock is A bit Undervalued RIght now.. Institutions have price targets of 42~-48 back on the Covid-low-trendline .. I dont see much Downside as Compared to upside. Dip below 35.99 ~ 35.70 range Twice , back up to 36.30 <---- 50+ cent gap ups. With Covid vaccine News coming any day now - Its this could be the next play. No matter which company has the vaccine - I think its likely any Big Pharma Companies Will get some Contracts to help produce the it. this stock is owned 77% By instutionals, With 3m Avg. Volume of shares being traded every day (very liquid) Whenever the Tutes' are bullish on a stock you know something big is coming! Adios Migos and GL' trading <--- This is just my personal idea/Reference chart. If your reading, have a good day! peace.
NYSE:GSKLong
by dekirby4
MGM Clearly Bullish, Get In Before Labor Day!MGM's growth has been fenominal through the past month as it climbed to new record highs. We seem to be hitting a respectful resistance, but now we have a even more respectul consolidation. I cant see MGM retesting another other supply levels in the future, as these next few days will look good for vegas, and especially the ballagio! People from all across the west are booking rooms for labor day as they are confirmed "Travel safe during COVID-19" (Trip Advisor). This is an extremely undervalued stock and I have high expectation for the upcoming week.
NYSE:MGMLong
by ArticaAnalytica
Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. DAILY CHART IS BULLISH OBV is Bullish MACD turned up Bullish RSi crossed center line and turned up, Bullish PMO is turning up, Bullish This little stock could spike hard. Best of luck everyone! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Bullish CHarts - Undervalued, $1.1 B in Sales, 97.3K New UsersEndurance International Group Holdings, Inc., together with its subsidiaries, provides cloud-based platform solutions for small-and medium-sized businesses in the United States and internationally. The company operates in three segments: Web Presence, Domain, and Email Marketing. It offers Web hosting services, including entry-level shared hosting, and virtual private server and dedicated hosting solutions; Website building tools; domain registration, management, and resale services; malware protection solutions to protect subscribers' Websites from viruses, malicious code, and other threats; and backup control solutions that enable subscribers to schedule, maintain, manage, and restore backups of their online data and Websites. The company also provides email marketing solutions that enable subscribers to communicate with their customers and potential customers through email; products that enables subscribers to sell their products and services online, including secure and encrypted payments, shopping carts, inventory management, online marketplace listing solutions, payment processing and related services, and mobile payments; and search engine optimization and marketing solutions. In addition, it offers solutions that allow subscribers to have their Websites and email marketing campaigns rendered on mobile devices; tools and services that enable subscribers to communicate with their customers and potential customers through social networks; business productivity tools that include professional email, word processing and presentation software, online storage, shared calendars, and video meetings; control panels and dashboards that offer subscribers with tools to analyze activity on their Websites; and professional services, including Website design, marketing, social media management, and Website migration services. The company was founded in 1997 and is headquartered in Burlington, Massachusetts. Many traders may not realize, this company owns some prominent & well known assets including CONSTANT CONTACT, BLUEHOST, HOSTGATOR & DOMAIN.COM among others. Many of these services we all use on a daily basis. On 07/14/20, Endurance announced Prelim. Q2 Sales of $274 Million, Net Subscriber Additions of 97,3K, and FY20 Sales of $1.1 BILLION On 07/15/20, Credit Suisse Lifted the price target on Endurance to $9.00 - (I think this is very conservative especially after seeing the assets the company owns) The Daily Chart looks BULLISH 50-Day MA is about to cross up and over the 200-Day MA, BULLSIH Volume is Green, Bullish PMO is Bullish MACD is Bullish RSI is Bullish Stochastic is Bullish OBV is Bullish Accumulation is Bullish Folks, if you look back at our previous research picks, we've made a lot of great calls. Look at APT, WRTC & SPCE today, to name a few. We think this stock is worth at minimum, $15 to $20 a share after looking at the assets they own. We think the assets are worth more than the stock price right now. CONSTANT CONTACT, BLUEHOST & HOSTGATOR are very well known in the technology industry. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
ELong
by HotCharts
Timeline: NIO vs. TSLA = NIO Target $350 to $500Don't shoot the messenger! I have a timeline of Tesla below which should put a price target on NIO North of $400 to $500 a share. www.thestreet.com As we stand today, NIO is much more successful than Tesla ever was and at this time, or there a bouts, compared to Tesla at or around the same time period in production & sales, Tesla was trading north of $360 a share and only delivered 2,400 cars compared to NIO delivering over 46,000 vehicles. "Entering 2018 Tesla faced several difficulties. Missed predictions had led investors to dump the company's stock, and in the middle of 2017 it lost more than 5% of its value in a collapse worth $12 billion. By January, 2018 Tesla was producing its Model 3 sedans at a fraction of the rate it had anticipated. Over a three-month period the company managed to finish and ship 2,400 cars after promising consumers and investors that it could complete more than 5,000 per week." On 07/02/2020, NIO announced as of June 30, NIO delivered 46,082 vehicles with 14,169 already delivered for 2020. These sales figures topple what Tesla sold and at or around the same time period, Tesla stock spiked to around $389.61. These are real figures from the Tesla timeline I have listed herein and using monthly stock charts for Tesla's stock price at that time period. NIO is also in much better financial condition than Tesla ever was at or around the same time in the production and sales cycle / timeline. Folks, when you look at the monthly stock prices for Tesla, and compare the timeline link I have herein, NIO is extremely cheap and deeply undervalued at current levels. Also, NIO has the Chinese Government behind them. Tesla, at or around when the company started, only raised $500 million from a DOE loan and Tesla was burning cash like water. NIO just raised almost $1 Billion in funding. NIO is financially in a better place than what Tesla ever was. The way I see it, the Chinese Government will not let NIO fail to Tesla, a USA auto company. In my opinion, after researching Tesla vs. NIO, I personally think NIO should be trading at or around $350 to $500 a share with their financial and sales figures. Best of luck longs! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:NIOLong
by HotCharts
12
Virgin Secures Financial Package of $1.5 Billion - Huge Win!Just an FYI... If anyone missed this today... At approx. 1:59 PM today, news was announced that Richard Branson Secured a financial package for Virgin Atlantic of about $1.5 Billion. www.barrons.com This is also great news for Virgin Galactic Holdings, Inc. because it takes financial pressure off all the Richard Branson companies as a whole. Also, on another note... I've heard rumors the FAA gave Virgin Galactic the long awaited license it needs for space travel. So we should have some great news forthcoming! Daily Chart SPCE is trading above the cloud and bounced up off support today to close up for the day, +0.33 at $18.43. PMO is Bullish RSI is Bullish OBV is Bullish Accumulation is Bullish Where's the stock going from here? My guess...to the moon! Best of luck longs! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:SPCELong
by HotCharts
Bullish Charts - Golden Cross, July 6 Conf CallObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland. On 06/29/20, ObsEva announced it will hold a conference call to discuss results from Phase 3 PRIMROSE 1 and PRIMROSE 2 clinical trials evaluating their drug Linzagolix in women with Uterine Fibroids. I personally think the conference call will be Bullish because on 07/01/20, ObsEva and Yuyuan BioScience Technology announced submission of the PRE-IND Dossier for Nolasiban with Chinese NMPA. This company has a few things going on that could be a catalyst for the stock moving into July 6, next week. Daily Chart is Bullish 50-Day MA just crossed up above the 200-Day MA - I believe this cross just happened today on above average volume. MACD is turning up, Bullish RSI is Bullish Stochastic is Bullish The Cloud indicators are all Bullish as seen below. 8-May-20 3.36 Bullish Kumo Breakout 5-May-20 2.95 Bullish Senkou Span Cross 4-May-20 2.41 Bullish Kijun Sen Cross 29-Apr-20 2.55 Bullish Tenkan/Kijun Cross 20-Apr-20 2.10 Bullish Chikou Span Cross Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
OLong
by HotCharts
1